Amphastar Pharmaceuticals to Present at the Wells Fargo 2020 Virtual Healthcare Conference
September 03 2020 - 4:05PM
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that
Bill Peters, CFO, Dan Dischner, Vice President of Corporate
Communications and Human Resources, and Tony Marrs, Sr. Vice
President Regulatory Affairs and Clinical Operations will
participate in an Analyst-Moderated fireside chat at the Wells
Fargo 2020 Virtual Healthcare Conference on Thursday, September 10,
2020 at 3:20 p.m. Eastern Time.
This presentation will be made available with a
live webcast and may be accessed by visiting Amphastar’s
Pharmaceuticals website at http://ir.amphastar.com . This webcast
will be available for 90 days following the presentation.
About Amphastar:
Amphastar is a specialty pharmaceutical company that focuses
primarily on developing, manufacturing, marketing, and selling
technically-challenging generic and proprietary injectable,
inhalation, and intranasal products. Additionally, the Company
sells insulin active pharmaceutical ingredient products. Most of
the Company’s finished products are used in hospital or urgent care
clinical settings and are primarily contracted and distributed
through group purchasing organizations and drug wholesalers. More
information is available at the Company’s website at
www.amphastar.com.
The Amphastar Pharmaceuticals’ logo and other trademarks or
service marks of Amphastar Pharmaceuticals, Inc., including,
but not limited to Primatene®, Amphadase® and Cortrosyn®, are the
property of Amphastar Pharmaceuticals, Inc.
Forward-Looking Statement:
All statements in this press release and in the conference call
referenced above that are not historical are forward-looking
statements, including, among other things, statements relating to
the Company’s expectations regarding future financial performance,
backlog, sales and marketing of its products, market size and
growth, the timing of FDA filings or approvals, including the DMFs
of ANP, the timing of product launches, acquisitions and other
matters related to its pipeline of product candidates, its share
buyback program and other future events, such as the impact of the
COVID-19 pandemic and related responses of business and governments
to the pandemic on our operations and personnel, and on commercial
activity and demand across our business operations and results of
operations. These statements are not historical facts but rather
are based on Amphastar’s historical performance and its current
expectations, estimates, and projections regarding Amphastar’s
business, operations and other similar or related factors. Words
such as “may,” “might,” “will,” “could,” “would,” “should,”
“anticipate,” “predict,” “potential,” “continue,” “expect,”
“intend,” “plan,” “project,” “believe,” “estimate,” and other
similar or related expressions are used to identify these
forward-looking statements, although not all forward-looking
statements contain these words. You should not place undue reliance
on forward-looking statements because they involve known and
unknown risks, uncertainties, and assumptions that are difficult or
impossible to predict and, in some cases, beyond Amphastar’s
control. Actual results may differ materially from those in
the forward-looking statements as a result of a number of factors,
including those described in Amphastar’s filings with the
Securities and Exchange Commission, including in the Annual Report
on Form 10-K for the year ended December 31, 2019 filed with the
SEC on March 16, 2020. In particular, the extent of COVID-19’s
impact on our business will depend on several factors, including
the severity, duration and extent of the pandemic, as well as
actions taken by governments, businesses, and consumers in response
to the pandemic, all of which continue to evolve and remain
uncertain at this time. You can locate these reports through the
Company’s website at http://ir.amphastar.com and on the SEC’s
website at www.sec.gov. The forward-looking statements in
this release speak only as of the date of the release. Amphastar
undertakes no obligation to revise or update information in this
press release or the conference call referenced above to reflect
events or circumstances in the future, even if new information
becomes available or if subsequent events cause Amphastar’s
expectations to change.
Contact:
Bill PetersChief Financial
Officer(909) 476-3416
Amphastar Pharmaceuticals (NASDAQ:AMPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amphastar Pharmaceuticals (NASDAQ:AMPH)
Historical Stock Chart
From Sep 2023 to Sep 2024